Patients with glaucoma or ocular hypertension implanted with SpyGlass Pharma’s Drug Delivery Platform showed a mean 43.7% reduction in IOP at 18 months, compared to baseline, the company reported at the recent Eyecelerator Ophthalmic Innovation Conference in Chicago.

The Spyglass system includes an IOL that contains drug-eluting pads attached to each haptic. It is designed to deliver 3 years of bimatoprost to targeted tissues. Data from the first-in-human study, which involved 23 glaucoma or ocular hypertension patients who were implanted with the lens during cataract surgery, showed that all patients achieved >20% reduction in IOP and remained off topical medications at 18 months. Additionally, 96% of patients achieved IOP levels at or below 18 mmHg. No product-related adverse events were reported, the company said. 

According to SpyGlass Pharma, patients in the first-in-human study will continue to be followed over time, and the company will provide longer-term data in 2025. A Phase1/2 study (NCT06120842) has enrolled 201 participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. It will compare the Spyglass system to treatment with timolol maleate ophthalmic solution.